4//SEC Filing
GOLD MITCHELL 4
Accession 0001626199-24-000025
CIK 0001626199other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 6:08 PM ET
Size
9.6 KB
Accession
0001626199-24-000025
Insider Transaction Report
Form 4
GOLD MITCHELL
DirectorExecutive Chairman and CEO10% Owner
Transactions
- Award
Stock Option (Right to buy)
2024-01-04+240,000→ 240,000 totalExercise: $18.33Exp: 2034-01-03→ Common Stock (240,000 underlying) - Award
Common Stock
2024-01-04+96,000→ 96,000 total
Holdings
- 2,627,157(indirect: Alpine ImmunoSciences, L.P.)
Common Stock
Footnotes (5)
- [F1]Received grant of restricted stock units ("RSUs") for no consideration. One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025 July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to the Reporting Person continuing to be a Service Provider through each such date.
- [F2]Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
- [F3]The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F4]The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
- [F5]One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
Documents
Issuer
ALPINE IMMUNE SCIENCES, INC.
CIK 0001626199
Entity typeother
Related Parties
1- filerCIK 0001242882
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 6:08 PM ET
- Size
- 9.6 KB